RG1662

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

45 competitors in Down Syndrome

#DrugCompanyPhaseTrials

1

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Approved

12

Wellcovorin

GGlaxo Dba Glaxosmithkline

Approved

—3

Keppra

UCB

Phase 3

14

Aquasol E

NNational Eye Institute (NEI)

Phase 3

15

Aricept

Eisai

Phase 3

26

Donepezil Hydrochloride

Eisai

Phase 3

17

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

—8

Folinic Acid

Roche

Phase 3

19

Namenda

AbbVie

Phase 2

210

Quillivant XR

Pfizer

Approved

1Show 22 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Down syndrome3 trials

A Study of RG1662 in Individuals With Down Syndrome

Completed·Roche·Phase 1·NCT01436955·35 enrolled

A Molecular and Functional Brain Imaging Study in Individuals With Down Syndrome and Healthy Controls Following Single Dose RG1662

Completed·Roche·Phase 1·NCT01667367·13 enrolled

A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)

Completed·Roche·Phase 2·NCT02024789·173 enrolled

Tics2 trials

A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers

Completed·Roche·Phase 1·NCT01684891·6 enrolled

A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy Subjects

Completed·Roche·Phase 1·NCT02470832·12 enrolled

Metformin1 trial

A Study of the Effect of RG1662 on Metformin in Healthy Volunteers

Completed·Roche·Phase 1·NCT02342925·17 enrolled

TED1 trial

Comparative Bioavailability Study of Film-coated Tablet and Granule Formulations of RG1662

Completed·Roche·Phase 1·NCT02194244·18 enrolled

Details

Drug Info

Related News